Semler Scientific Inc. $SMLR Shares Purchased by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. has significantly increased its stake in Semler Scientific Inc. by 226.1%, now owning approximately 1.65% of the company valued at $5.74 million.
• Semler Scientific's recent quarterly earnings report showed an impressive $5.04 EPS, surpassing analysts' expectations and indicating a strong net margin of 86.20%.
• Analysts have varied opinions on Semler Scientific's stock, with price targets ranging from $60.00 to $101.00, reflecting mixed sentiments in the market regarding its future performance.

Charles Schwab Investment Management Inc. boosted its position in Semler Scientific Inc. (NASDAQ:SMLR - Free Report) by 226.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,576 shares of the company's stock after buying an additional 109,951 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.65% of Semler Scientific worth $5,740,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Interchange Capital Partners LLC purchased a new position in Semler Scientific in the 1st quarter valued at $46,502,000. Driehaus Capital Management LLC purchased a new position in Semler Scientific in the 4th quarter valued at $10,122,000. Nuveen Asset Management LLC grew its position in Semler Scientific by 396.9% in the 4th quarter. Nuveen Asset Management LLC now owns 124,548 shares of the company's stock valued at $6,726,000 after buying an additional 99,482 shares during the last quarter. Stifel Financial Corp grew its position in Semler Scientific by 107.9% in the 4th quarter. Stifel Financial Corp now owns 52,141 shares of the company's stock valued at $2,816,000 after buying an additional 27,062 shares during the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Semler Scientific in the 1st quarter valued at $1,874,000. 49.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on SMLR shares. Benchmark started coverage on shares of Semler Scientific in a research report on Tuesday, July 8th. They set a "buy" rating and a $101.00 target price on the stock. Wall Street Zen lowered shares of Semler Scientific from a "buy" rating to a "sell" rating in a research report on Thursday, May 22nd. Maxim Group upgraded shares of Semler Scientific to a "strong-buy" rating and set a $95.00 target price on the stock in a research report on Wednesday, July 9th. Finally, Cantor Fitzgerald decreased their target price on shares of Semler Scientific from $61.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $81.75.

Semler Scientific Price Performance

Shares of NASDAQ:SMLR traded down $0.99 during midday trading on Friday, hitting $29.64. 483,376 shares of the stock were exchanged, compared to its average volume of 577,033. The stock has a market cap of $438.97 million, a P/E ratio of 12.20 and a beta of 1.34. The company has a current ratio of 0.60, a quick ratio of 0.58 and a debt-to-equity ratio of 0.25. Semler Scientific Inc. has a twelve month low of $21.77 and a twelve month high of $81.56. The company has a 50 day moving average price of $37.34 and a 200-day moving average price of $37.20.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $5.31. The business had revenue of $8.22 million during the quarter, compared to the consensus estimate of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.